Drug · CHEMBL545

ALCOHOL

7 sourcespipelines-2026-09-18-0.3.1

Cite this record

ConductScience Library. ALCOHOL. Drugs and targets, record CHEMBL545. Release pipelines-2026-09-18-0.3.1, 18 Sept 2026. https://conductscience.org/library/drugs/CHEMBL545

On this page

Drug

Names and IDs as ChEMBL gives them, through Open Targets.

Name: ALCOHOL; ChEMBL
ChEMBL ID: CHEMBL545; ChEMBL
Type: Small molecule; ChEMBL
Brand names: Ablysinol, Alcohol component of avagard, Alcohol component of hbn-1 ethanol, Methylated mineral, Spirigel, Surg; ChEMBL
Other names: Alcohol 190 proof, Alcohol 95%, Alcohol anhydrous, Alcohol denat., Alcohol denatured, Alcohol determination--alcohol, Alcohol, absolute, Alcohol, dehydrated, Alcohol, denatured, Alcohol,dehydrated, Alcohol,denatured, Alcohol,ethyl, Alcohol,sda, Alcoholum, Anhydrous ethanol, B3324, Dehydrated alcohol, Dehydrated ethanol, E1510, Edible alcohol, Ethanol, Ethanol in alcoholic beverages, Ethanol, anhydrous, Ethanol, dehydrated, Ethanolum, Ethyl alcohol, Ethyl alcohol, absolute, Ethyl alcohol, dehydrated, Ethylicum, FEMA NO. 2419, Grain alcohol, NCI-C03134, NSC-85228, PM-6193-200, Sd alcohol, Tecsol, Vodka; ChEMBL
DrugBank: DB00898; DrugBank
InChIKey: LFQSCWFLJHTTHZ-UHFFFAOYSA-N; ChEMBL
Open Targets' highest stage: Approval, for 6 of its 41 diseases, from DailyMed, PMDA and TTD; Open Targets

Targets0

The targets ChEMBL's mechanism records give for the drug, through Open Targets. A mechanism record says what the drug acts on, not how strongly.

None in this release.

Diseases41

The diseases Open Targets' clinical reports study the drug for, the most trial reports first. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Disease	Open Targets' stage	Stage reported by	Reports	Of them trials	Its drugs
hypertensive disorder	Phase 3	ClinicalTrials.gov	5	5	https://conductscience.org/library/drugs?q=MONDO_0005044
type 2 diabetes mellitus	Phase 2	ClinicalTrials.gov	4	4	https://conductscience.org/library/drugs?q=MONDO_0005148
hepatocellular carcinoma	Approval	PMDA	4	3	https://conductscience.org/library/drugs?q=MONDO_0007256
COVID-19	Phase 3	ClinicalTrials.gov	3	3	https://conductscience.org/library/drugs?q=MONDO_0100096
infection	Approval	DailyMed	3	2	https://conductscience.org/library/drugs?q=EFO_0000544
Pancreatic cysts	Phase 3	ClinicalTrials.gov	2	2	https://conductscience.org/library/drugs?q=HP_0001737
herpes labialis	Phase 2	ClinicalTrials.gov	2	2	https://conductscience.org/library/drugs?q=MONDO_0043653
intoxication	Phase 2	ClinicalTrials.gov	2	2	https://conductscience.org/library/drugs?q=EFO_0009574
osteoarthritis, knee	Unknown	ClinicalTrials.gov	2	2	https://conductscience.org/library/drugs?q=MONDO_0005416
Chronic pain	Approval	DailyMed and TTD	8	1	https://conductscience.org/library/drugs?q=HP_0012532

1 to 10 of 41Source Open Targets

See all 41 diseases

Trials177

Trials whose record names the drug by a name ChEMBL states, posted results first, then the largest. Open Targets read each trial's text to find its drugs. 3 more rest on that reading alone and are shown because the trials' posted result groups or NLM's indexing of their papers name the drug. 12 more that Open Targets linked to it are not shown, since the release's checks do not confirm them.

Trial	Title	Phase	Participants	Results first posted	Named as	Linked by	Source
NCT02938377	Alcohol Research Consortium in HIV-Intervention Research Arm	Phase 4	4,985	2025-03-10	alcohol pharmacotherapy	Open Targets' reading, confirmed by the trial's result groups	ClinicalTrials.gov
NCT03449095	Understanding Alcohol Reward in Social Context		640	2024-07-31	alcohol	Its name	ClinicalTrials.gov
NCT01985321	Safety and Efficacy of Merlin (Ethanol and Glycolic Acid Mixture) for the Treatment of Cold Sores	Phase 2	469	2015-05-28	ethanol, ethanol and glycolic acid mixture	Its name	ClinicalTrials.gov
NCT03192306	Safety and Efficacy of Merlin (Ethanol and Glycolic Acid Mixture) for Episodic Treatment of Cold Sores	Phase 2	451	2018-08-16	ethanol	Its name	ClinicalTrials.gov
NCT03503773	The TARGET BP OFF-MED Trial	Phase 2	350	2024-10-04	alcohol	Its name	ClinicalTrials.gov
NCT01898221	Vein of Marshall Ethanol Infusion for Persistent Atrial Fibrillation	Phase 3	343	2025-08-21	ethanol	Its name	ClinicalTrials.gov
NCT03655717	Using Imaging to Assess Effects of THC on Brain Activity		316	2022-07-28	ethanol	Its name	ClinicalTrials.gov
NCT00183170	Residual Effects of Intoxication on Student Performance	Phase 2	239	2020-12-04	alcohol	Its name	ClinicalTrials.gov
NCT00612352	Intravenous Alcohol Administration Using BrAc Method in Healthy Subjects With and Without a Family History of Alcoholism		180	2017-02-24	ethanol	Its name	ClinicalTrials.gov
NCT00515294	Acute and Residual Effects of Caffeinated Beer	Phase 1/2	154	2017-06-28	alcohol	Its name	ClinicalTrials.gov

1 to 10 of 177

See all 177 trials

Comparisons in its trials38

Comparisons Trial comparisons calculated in the trials whose record names the drug, most participants first. A comparison in one of its trials does not always compare the drug, so read the two groups.

Comparison	Group 1, with the outcome	Group 2, with the outcome	Participants	Trial	Source
Alcohol Administration vs Control Beverage Administration: deaths from any cause	0 of 320	0 of 320	640	NCT03449095	Trial comparisons
Alcohol Administration vs Control Beverage Administration: serious adverse events	0 of 320	0 of 320	640	NCT03449095	Trial comparisons
Alcohol vs Placebo: serious adverse events	0 of 193	0 of 193	386	NCT00183170	Trial comparisons
Standard Catheter Ablation Patient Group vs Vein of Marshall and Standar Procedure: Number of Patients With Clinical Success	84 of 158	115 of 185	343	NCT01898221	Trial comparisons
Standard Catheter Ablation Patient Group vs Vein of Marshall and Standar Procedure: Amount of Treated Subjects With Freedom of Symptomatic Post-procedural AF or Flutter at 12 and 15 Months Post Procedure and Less Than 1 Min/Day of AF or Flutter on 4-week EKG Monitor.	60 of 158	91 of 185	343	NCT01898221	Trial comparisons
Standard Catheter Ablation Patient Group vs Vein of Marshall and Standar Procedure: deaths from any cause	2 of 158	4 of 185	343	NCT01898221	Trial comparisons
Standard Catheter Ablation Patient Group vs Vein of Marshall and Standar Procedure: serious adverse events	29 of 158	38 of 185	343	NCT01898221	Trial comparisons
Family History Positive vs Family History Negative: serious adverse events	0 of 65	0 of 115	180	NCT00612352	Trial comparisons
Merlin - Ethanol/Glycolic Acid Solution vs Ethanol: serious adverse events	0 of 90	0 of 83	173	NCT01985321	Trial comparisons
Merlin - Ethanol/Glycolic Acid Solution vs Ethanol: Number of Treatment Related Adverse Events	9 of 89	3 of 83	172	NCT01985321	Trial comparisons

1 to 10 of 38

See all 38 comparisons in its trials

Papers from its trials91

The papers the trials whose record names the drug list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
37993679	RESULT	1	PubMed
35268545	RESULT	1	PubMed
34398686	RESULT	1	PubMed
34173005	RESULT	1	PubMed
33605538	RESULT	1	PubMed
33516710	RESULT	1	PubMed
33397141	RESULT	1	PubMed
33116703	RESULT	1	PubMed
32472620	RESULT	1	PubMed
31891860	RESULT	1	PubMed

1 to 10 of 91

See all 91 papers from its trials

Tests in its trials20

The tests ConductCognition runs that the trials whose record names the drug name in their registered outcomes, as ScienceGraph matched them. ConductCognition's list names the tests it runs, not every test a trial used.

Test	Trials naming it as an outcome	As a primary outcome	Source
Go/No-Go Task	4	2	ConductCognition
1-Back Task	4	3	ConductCognition
Stop-Signal Task	4	3	ConductCognition
Symbol Coding	4	2	ConductCognition
Continuous Performance Test	3	0	ConductCognition
2-Back Task	3	2	ConductCognition
Psychomotor Vigilance Task	3	1	ConductCognition
Verbal Learning	3	1	ConductCognition
Choice Reaction Time	2	2	ConductCognition
Hidden Path Learning	2	2	ConductCognition

1 to 10 of 20

See all 20 tests in its trials

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
ClinicalTrials.gov: 2026-11-05; ClinicalTrials.gov
Results, from AACT: 2026-03-23; AACT
Papers the trials list, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
Tests named in the trials, as ScienceGraph matched them: 2026-11-12; ConductCognition

Sources 7

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ConductCognition's list of its testsOur own data
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ConductCognition's list of its testsOur own data: ConductCognition's list of its tests, https://conductcognition.com
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this drug from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/drugs/v1/CHEMBL545

GET https://conductscience.org/api/drugs/v1/CHEMBL545/diseases?page=2

API reference For AI assistants